Medical AI Company VUNO Reports Profit in Q3, Driven by DeepCARS Growth
- 11 Consecutive Quarters of Revenue Growth; Q3 Revenue Exceeds KRW 10 billion for the First Time SEOUL, South Korea, Nov. 12, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced that it was profitable in the third quarter of 2025, recording consolidated revenue ofKRW 10.8 bil...
VUNO Partners with European Firms to Advance DeepCARS® Market Entry in Europe
- Strategic MOU enhances market access and extends reach to over 900 hospitals across the region SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austria...
VUNO's AI-Powered Cardiac Arrest Risk Management System Earns CE MDR and UKCA Certifications
* Early Regulatory Approval Accelerates Expansion Plans in Europe and the Middle East SEOUL, South Korea, May 12, 2025 /PRNewswire/ -- VUNO, a leading South Korean medical AI company, announced today that its flagship AI-powered cardiac arrest risk management system VUNO Med®-DeepCARS®(DeepCARS...
VUNO PRESENTS CUTTING-EDGE AI BRAIN TECHNOLOGY AT AAIC - ANALYZING MRI SCANS IN <1 MINUTE TO SUPPORT DIAGNOSIS OF ALZHEIMER'S DISEASE
Potential partners are invited to explore collaboration opportunities with VUNO
Med®-DeepBrain®, a highly accurate AI solution for research and clinical
settings.
MARLBOROUGH, Mass., June 17, 2024 /PRNewswire/ -- VUNO
VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®
SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean
medical AI company has received 510(k) clearance from the Food and Drug
Administration (FDA) for its AI-powered brain quantification device, VUNO
Med®-DeepBrain®.
VUNO's First AI-based Prospective Study Results Published in Critical Care
SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company announced that its AI-based cardiac arrest risk management system, VUNO Med®-DeepCARS™, has proven its clinical validity for the first time through a prospective study utilizing Real World Data(RWD). <...
VUNO Showcases their AI Solutions and Research Results at RSNA 2022
SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- VUNO Inc., a leading South Korean artificial intelligence (AI) developer, announced that it will participate in the Radiological Society ofNorth America 2022 (RSNA 2022). This year, VUNO will focus on highlighting how their breakthrough AI technol...
VUNO Boasts of its AI Solutions and Research Results at RSNA 2021
SEOUL, South Korea, Nov. 28, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer VUNO Inc. announced that it will join the Radiological Society ofNorth America 2021 (RSNA 2021), one of the biggest annual events, featuring a series of industry symposia in radiology. This year,...
VUNO Signs Another Deal with Samsung Electronics to Incorporate AI-assisted Solutions into Samsung's Premium Ceiling Type Digital Radiography System
SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc., announced today that the company closed a deal with global medical device manufacturer, Samsung Electronics Co., Ltd., to embed VUNO's artificial intelligence-driven chest X-ray diagno...
MFDS Greenlights VUNO Med®-DeepCARS™, AI Medical Device for Cardiac Arrest Prediction
SEOUL, South Korea, Aug. 24, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO Med®–DeepCARS™, an AI medical device for cardiac arrest predictio...
